This financial award will go directly to support this crucial research that offers expect preventing blindness, restoring sight, and improving the quality of life for sufferers of AMD. I thank The New York Stem Cell Foundation for recognizing this important work and for its support of translational stem cell analysis. Coffey was selected by a jury headed by Douglas A. Melton, PhD, Co-Director of the Harvard Stem Cell Institute and an associate of the NYSCF Medical Advisory Table who noted: The jury was impressed with the high caliber of applicants for this prize and the range of exciting work happening in stem cell analysis. We congratulate Professor Coffey and desire him achievement as his approach to treating Age-Related Macular Degeneration heads toward clinical trials. Other jury people had been: Christine Mummery, PhD, Chair of the Section of Embryology and Anatomy in Leiden University Medical Center in the Netherlands; Lorenz Studer, MD, Director of the Sloan-Kettering Middle for Stem Cell Biology; and Irving Weissman, MD, Director of the Institute for Stem Cell Biology and Regenerative Medication at the Stanford College of Medicine.YERVOY: Risk Evaluation and Mitigation Technique ‘Bristol-Myers Squibb is focused on the safe and suitable use of our medications,’ stated Annalisa Jenkins, senior vice president global medical, Bristol-Myers Squibb. ‘Within the U.S. Acceptance of YERVOY, we’ve collaborated with the FDA on the advancement of a Risk Evaluation and Mitigation Technique to help inform individuals and providers about essential safety risks connected with YERVOY.’ The YERVOY Risk Evaluation and Mitigation Technique includes a Communication Intend to inform potential prescribers and supportive health care providers about serious effects linked with YERVOY. To aid this communication strategy, Bristol-Myers Squibb has set up a system that may enable the firm to provide these educational components to the correct healthcare professional during product order.